{"podcast":{"title":"HCPLive Podcasts","slug":"hcplive-podcasts-19526","podcast_index_feed_id":19526,"rss_url":"https://audioboom.com/channels/5004077.rss","website_url":"https://audioboom.com/channels/5004077","image_url":"https://audioboom.com/i/40144427.png","author":"HCPLive.com","episode_count":243,"summary":"Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.","last_synced_at":null,"page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526"},"episode":{"title":"Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2","slug":"joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2","published_at":"2026-05-28T19:03:00+00:00","page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2","show_page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526","url":"https://audioboom.com/posts/8909063","audio_url":"https://audioboom.com/posts/8909063.mp3?modified=1779994838&sid=5004077&source=rss","summary":"In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.","meta_description":"In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Bus…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1674,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hcplive-podcasts-19526/joint-ventures-glp-1-receptor-agonists-from-metabolic-drug-to-immunomodulator-part-2.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}